|
1
|
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
|
Blood
|
2011
|
3.58
|
|
2
|
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
|
Blood
|
2012
|
1.58
|
|
3
|
Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
|
Mol Cancer Ther
|
2012
|
0.89
|
|
4
|
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo.
|
Mol Cancer Ther
|
2010
|
0.86
|
|
5
|
The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.
|
J Pharmacol Exp Ther
|
2013
|
0.81
|
|
6
|
Probing the effects of DNA-protein interactions on DNA hole transport: the N-terminal histone tails modulate the distribution of oxidative damage and chemical lesions in the nucleosome core particle.
|
Biochemistry
|
2012
|
0.78
|
|
7
|
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
|
Appl Immunohistochem Mol Morphol
|
2015
|
0.75
|